UCAR-T cell therapy(PersonGen BioTherapeutics)

N/A

Report date: 2022/04/01 18:05:37

Base Information

Drug NameUCAR-T cell therapy(PersonGen BioTherapeutics)

Drug Alias NameTAA3-UCAR-gamma delta T cell therapyTAA3-UCAR-γδ TTumour associated antigens targeting UCAR gamma delta T cell therapy(PersonGen BioTherapeutics)UCAR gamma delta T cell therapy

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPersongen Biotherapeutics

China Registration ClassN/A

Develop Information

Active CompaniesPersongen Biotherapeutics

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A